Table 2 Clinical outcomes among US-enrolled induction therapy trial participants based on integrated trial records and OPTN follow-up data
rATG % | Basiliximab % | P | |
|---|---|---|---|
Outcomes at 1 year | |||
Acute rejection | 14.3 % | 22.8 % | 0.08 |
Patient survival | 94.5 % | 95.7 % | 0.74 |
All-cause graft survival | 89.0 % | 85.9 % | 0.47 |
Freedom from acute rejection, graft failure or death | 80.0 % | 68.5 % | 0.04 |
Any malignancy | 1.1 % | 1.1 % | 0.99 |
Post-transplant lymphoproliferative disorder | 0 | 0 | 1.00 |
Non-melanoma skin cancer | 1.1 % | 0 | 0.31 |
Non-skin cancer | 0 | 1.1 % | 0.32 |
Outcomes at 5 years | |||
Acute rejection | 21.0 % | 32.8 % | 0.07 |
Patient survival | 72.5 % | 75.0 % | 0.64 |
All-cause graft survival | 67.5 % | 60.6 % | 0.32 |
Freedom from acute rejection, graft failure, or death | 57.6 % | 44.2 % | 0.04 |
Any malignancy | 4.5 % | 4.5 % | 0.97 |
Post-transplant lymphoproliferative disorder | 1.1 % | 0 | 0.31 |
Non-melanoma skin cancer | 2.3 % | 1.1 % | 0.54 |
Non-skin cancer | 2.3 % | 3.3 % | 0.67 |
Outcomes at 10 years | |||
Acute rejection | 21.0 % | 32.8 % | 0.07 |
Patient survival | 52.8 % | 52.2 % | 0.92 |
All-cause graft survival | 34.3 % | 30.9 % | 0.56 |
Freedom from acute rejection, graft failure, or death | 32.6 % | 24.0 % | 0.09 |
Any malignancy | 9.5 % | 8.1 % | 0.75 |
Post-transplant lymphoproliferative disorder | 2.2 % | 0 | 0.15 |
Non-melanoma skin cancer | 3.6 % | 1.1 % | 0.30 |
Non-skin cancer | 6.0 % | 6.9 % | 0.79 |